Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Teva
Citi
US Army
Healthtrust
Colorcon

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 6,864,264

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,864,264
Title: 1-adamantyl chalcones for the treatment of proliferative disorders
Abstract:The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], ##STR1## wherein the substituents are as defined in the specification.
Inventor(s): Anderson; Gloria L. (Atlanta, GA), Kaimari; Tawfeq Abdul-Raheem (Kennesaw, GA)
Assignee:
Application Number:10/224,723
Patent Claims:see list of patent claims

Details for Patent 6,864,264

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up 2038-11-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,864,264

Country Patent Number Publication Date
United States of America 2005065152 Mar 24, 2005
United States of America 2006189580 Aug 24, 2006
United States of America 2009281196 Nov 12, 2009
United States of America 2011319483 Dec 29, 2011
United States of America 7563789 Jul 21, 2009
United States of America 8013020 Sep 06, 2011
United States of America 8450377 May 28, 2013
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
Boehringer Ingelheim
McKesson
Johnson and Johnson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.